The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2023

Filed:

Apr. 10, 2019
Applicant:

Akeso Biopharma, Inc., Guangdong, CN;

Inventors:

Zhongmin Maxwell Wang, Guangdong, CN;

Baiyong Li, Guangdong, CN;

Yu Xia, Guangdong, CN;

Peng Zhang, Guangdong, CN;

Assignee:

Akeso Biopharma, Inc., Guangdong, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/395 (2006.01); G01N 33/53 (2006.01); C12P 21/06 (2006.01); C12N 5/20 (2006.01); C12N 15/00 (2006.01); C07K 16/00 (2006.01); C07K 16/46 (2006.01); C07H 21/04 (2006.01); C07K 16/22 (2006.01); A61P 19/02 (2006.01); A61P 29/00 (2006.01); C07K 16/42 (2006.01);
U.S. Cl.
CPC ...
C07K 16/22 (2013.01); A61P 19/02 (2018.01); A61P 29/00 (2018.01); C07K 16/42 (2013.01); A61K 2039/505 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention discloses a monoclonal antibody against nerve growth factor, and an encoding gene and use thereof. The monoclonal antibody against nerve growth factor of the present invention comprises heavy chains comprising a heavy chain constant region and a heavy chain variable region, and light chains comprising a light chain constant region and a light chain variable region. The heavy chain variable region comprises three complementarity determining regions HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises three complementarity determining regions LCDR1, LCDR2 and LCDR3. The monoclonal antibody against nerve growth factor of the present invention can specifically bind to nerve growth factor, and can be used to detect the presence and/or level of nerve growth factor, as well as to prepare a drug for inhibiting the nerve growth factor-dependent proliferation of TF-1 cells, and to prepare a drug for treating or preventing at least one of neuropathic pain, chronic pain, and inflammatory pain, thus having good application prospects and marketing value.


Find Patent Forward Citations

Loading…